Evidence map›Paper›PMID 41515980›Full record

ReviewInternational journal of molecular sciences2025

Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds.

Carlos García-Estrada, Carlos Barreiro, Juan F Martín

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carlos García-EstradaDepartamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.ORCID 0000-0001-5617-9669
Carlos BarreiroIBIOLEÓN (Instituto de Investigación Biosanitaria de León), Hospital de León, Altos de Nava s/n, 24071 León, Spain.ORCID 0000-0001-7328-1630
Juan F MartínÁrea de Microbiología, Departamento de Biología Molecular, Facultad de Ciencias Biológicas y Ambientales, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer remains one of the leading causes of death worldwide, and resistance to conventional therapies underscores the need for the discovery of novel antitumor agents. The ongoing search for novel natural sources offers promising avenues for discovering unique anticancer compounds with new mechanisms of action. One of these natural sources is represented by fungi, a prolific group of endophytic and non-endophytic eukaryotes able to produce bioactive secondary metabolites, many of which exhibit potent antitumor properties. These natural compounds display diverse chemical structures including polyketides, terpenoids, alkaloids, amino acid-derived compounds, phenols, etc. Their mechanisms of action are equally varied, ranging from induction of apoptosis and cell cycle arrest to inhibition of angiogenesis and metastasis. In this review we describe some potential antitumor compounds of fungal origin, together with the characteristics and biosynthesis of three representative types of antitumor compounds produced by filamentous fungi: squalene-derived sterol-type antitumor agents, prenylated diketopiperazine antitumor metabolites and meroterpenoid antitumor compounds. The ongoing scientific debate regarding the presence of paclitaxel biosynthetic genes in fungi is also discussed. As drug resistance remains a challenge in cancer therapy, fungal compounds offer a valuable reservoir for the development of new chemotherapeutic agents with novel modes of action.

Indexed as

Antineoplastic AgentsBiological ProductsFungiNeoplasmsSecondary MetabolismAnimalsHumansTerpenesAntineoplastic AgentsBiological ProductsTerpenesandrastinsanticancerantitumorclavaric acidfumitremorgin Cfungipaclitaxelsecondary metabolites

Identifiers

PMID41515980
PMCPMC12785832

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.